Value Proposition
· Blood-based diagnostic strategy to quickly confirm disease
· Diagnostic potential is equivalent to current cumbersome clinical measurement
· Less costly than standard diagnostic methodologies
· Easily repurposed for monitoring progression and treatment response
Unmet Need
· Pulmonary hypertension (PH) has an estimated prevalence of 1-2 cases among one million Americans and a global incidence of about 1%. The incidence of PH increases up to 10% in individuals over the age of 65. Diagnostics and survival risk prediction for pulmonary hypertension require a comprehensive collection of clinical data including invasive cardiac catheterization, pulmonary function testing, measuring six-minute walk distance, scoring of clinical status, and measurements of NTproBNP. The multitude of required diagnostic benchmarks is a barrier to efficient and effective PH diagnosis and treatment, therefore, there is a strong need for more efficient diagnostic methodologies to be developed to alleviate the invasive and costly approach currently employed.
Technology Description
· Researchers at Johns Hopkins University have developed an efficient diagnostic methodology for pulmonary hypertension. This technology measures the levels of specific proteins within the blood using an elegant and facile to deploy ELISA. This invention can easily be repeated serially for diagnostics, disease progression, and monitoring therapeutic response to inform clinical management of PH.
Stage of Development
· In vitro proof-of-concept and validation studies have been completed.
Data Availability
· Data available upon request.
Publications:
